Minerva Seeks FDA Approval For Its Schizophrenia Candidate
Minerva Neurosciences Inc (NASDAQ:NERV) submitted a marketing application to the FDA for roluperidone for negative symptoms in patients with schizophrenia. “We…
Boosters Are Coming For Dangerous Omicron COVID-19 Variant. Here’s Who May Be Rolling Them Out
Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) have completed a submission to the FDA requesting Emergency Use Authorization for an omicron BA.4/BA.5-adapted COVID-19…
Belite Bio Starts Enrollment In Pivotal Lead Asset Study In Inherited Eye Disease
Belite Bio Inc (NASDAQ:BLTE) commenced enrollment for the U.S. Phase 3 trial of LBS-008 in patients with Stargardt Disease (STGD1), a…
Gilead’s Lenacapavir Scores European Approval For Pretreated HIV Patients After Manufacturing Delays
The European Commission has approved Gilead Sciences Inc’s (NASDAQ:GILD) lenacapavir for adults with multi-drug resistant HIV infection. The drug, branded as…
Cue Biopharma Shares Decline Following Initial-Stage Metastatic Cancer Study Kicks-off
Cue Biopharma (NASDAQ: CUE) has dosed the first patient in a Phase 1 dose escalation study evaluating CUE-102 for the treatment of patients with Wilms' Tumor 1 (WT1)-positive recurrent/metastatic cancers.
Minerva Seeks FDA Approval For Schizophrenia Candidate
Minerva Neurosciences (NASDAQ: NERV) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for roluperidone in the treatment of negative symptoms for patients with schizophrenia.
Belite Bio Shares Gain On Initiation Of Late-Stage Retinal Disease Study
Belite Bio (NASDAQ: BLTE) has initiated enrollment for the U.S. Phase 3 clinical trial of its lead asset LBS-008 in patients with Stargardt Disease (STGD1), a progressively blinding disease with no approved treatment.
Moderna to Supply 12M Doses of Omicron-Adapted COVID-19 Booster To Canada
Moderna Inc (NASDAQ:MRNA) will supply 12 million doses of its COVID-19 shot adapted to target the Omicron variant of the coronavirus…
Teleflex Beefs Up Its Bariatric Surgery Portfolio With This $170M Acquisition
Teleflex Incorporated (NYSE:TFX) has agreed to acquire Standard Bariatrics Inc for an upfront cash payment of $170 million and additional consideration of…